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Abstract
The eighth edition of the American Joint Committee on Cancer (AJCC8) stag-
ing manual has major changes in oral squamous cell carcinoma (OSCC). We
searched PubMed, OvidMedline, Scopus, and Web of Science for studies that
examined the performance of AJCC8 in OSCC. A total of 40 808 patients were
included in the studies of our meta-analysis. A hazard ratio (HR) of 1.87 (95%
CI 1.78-1.96) was seen for stage II, 2.65 (95%CI 2.51-2.80) for stage III, 3.46
(95%CI 3.31-3.61) for stage IVa, and 7.09 (95%CI 4.85-10.36) for stage IVb. A
similar gradual increase in risk was noted for the N classification. For the T
classification, however, there was a less clear variation in risk between T3 and
T4. AJCC8 provides a good risk stratification for OSCC. Future research should
examine the proposals introduced in the published studies to further improve
the performance of AJCC8.
KEYWORD S
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extranodal extension, N classification, oral squamous cell carcinoma (OSCC), prognosis,
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1 | INTRODUCTION
Oral cancer constitutes a life-threatening disease with a
high mortality rate. According to Global Cancer Statis-
tics, GLOBOCAN, there were 354 864 new cases of oral
cavity cancer causing 177 384 deaths during 2018.1
Smoking, in addition to chewing habits, is the main risk
factor for oral cavity cancer. Other risk factors that might
associate with the occurrence of oral cancer include, for
example, alcohol consumption and poor oral hygiene.2,3
In many countries, there is an increase in the incidence
of oral cancer in young people.4 Oral squamous cell carci-
noma (OSCC) is the most common histologic type of oral
cavity cancer. OSCC is usually treated with surgical
resection of the tumor and with consequent neck dissec-
tion when there is evidence of neck disease or the risk for
regional metastases is high. Adjuvant treatment (radio-
therapy with or without chemotherapy) is used in cases
with high-risk of poor prognosis. Indeed, patients eligible
for such an aggressive treatment should be selected care-
fully on case-by-case basis.
A proper cancer staging is an important step
toward individualized treatment approach. Current
staging of cancer is based on evaluation of extension of
tumor (T), involvement of lymph nodes (N) and distant
metastasis (M). Together, these three categories form
the TNM staging system that was released in a collabo-
ration between the American Joint Committee on Can-
cer (AJCC) and the Union for International Cancer
Control (UICC). This system is internationally accepted
as the universal system for staging and it strongly
influences treatment planning. According to the pub-
lishing history of AJCC (http://cancerstaging.org), the
first edition of AJCC Manual was published in 1977
and since then new editions were published to update
the staging of different cancers. For OSCC, the eighth
edition of AJCC staging manual (AJCC 8) that has
been recently released includes the most significant
changes in the classification for over 30 years. These
changes include the incorporation of depth of invasion
into T classification, and extranodal extension into N
classification.5 Such changes will influence the staging
of many cases of OSCC and that indeed will influence
the clinical decision making. Therefore, the impact of
the AJCC 8 staging system is an important topic of
research and its prognostic performance has recently
been evaluated in several studies. We sought to review
these studies systematically and to carry out meta-anal-
ysis of the accumulated evidence to conclude about the
utility of AJCC 8 in OSCC. We also discuss further
improvements of AJCC 8 based on proposals by the
published studies.
2 | METHODS
2.1 | Data search
We searched the databases of PubMed, OvidMedline,
Scopus, and Web of Science using the following search
terms: (“oral squamous cell carcinoma” OR “oral can-
cer”) AND (“American Joint Committee on Cancer” OR
“AJCC”). Two independent researchers (AA & OY)
screened the retrieved studies, excluding duplicates and
irrelevant studies. A study was considered relevant and
eligible for inclusion if it analyzed prognostic perfor-
mance of AJCC 8 in OSCC. The references of relevant
studies were searched manually.
According to the website of AJCC, the eighth edi-
tion was published in 2016, and therefore we limited
our database searching to the period from January
2016 until the date we conducted the literature search
(25 February 2019). Non-English articles and confer-
ence abstracts were excluded. From the relevant stud-
ies (Table 1), the following items were extracted: name
of first author, country, year of publication, number of
cases, stage of cases, category of TNM analyzed, main
treatment, percentage of cases that were upstaged due
to AJCC 8, main findings about AJCC 8, survival out-
come analyzed, and statistical values reported. The Pre-
ferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) were followed to ensure
proper search of literature.6
2.2 | Quality assessment
We used Reporting Recommendations for Tumor Marker
Prognostic Studies (REMARK)7 to evaluate the quality of
all eligible studies as previously described.8,9
2 ALMANGUSH ET AL.
T
A
B
L
E
1
Su
m
m
ar
y
of
st
u
di
es
th
at
ev
al
ua
te
d
th
e
pr
og
n
os
ti
c
si
gn
if
ic
an
ce
of
th
e
8t
h
ed
it
io
n
of
th
e
A
m
er
ic
an
Jo
in
t
C
om
m
it
te
e
on
C
an
ce
r
(A
JC
C
8)
st
ag
in
g
in
or
al
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a
(O
SC
C
)
F
ir
st
A
u
th
or
et
al
,
ye
ar
(C
ou
n
tr
y)
N
o.
of
ca
se
s
St
ag
e
8t
h
A
JC
C
an
al
yz
ed
M
ai
n
tr
ea
tm
en
t
%
of
ca
se
s
u
p
st
ag
ed
M
ai
n
fi
n
d
in
gs
re
ga
rd
in
g
p
ro
gn
os
ti
c
p
er
fo
rm
an
ce
of
A
JC
C
8
O
u
tc
om
e
H
R
(9
5%
C
I)
P
va
lu
e
D
ir
ve
n
et
al
,2
01
7
(A
us
tr
al
ia
)a
45
6
I-
IV
T
cl
as
si
fi
ca
ti
on
Su
rg
er
y
21
.9
%
Pr
og
n
os
ti
c
si
gn
if
ic
an
ce
of
T
cl
as
si
fi
ca
ti
on
of
A
JC
C
8
is
sa
m
e
w
h
et
h
er
de
pt
h
of
in
va
si
on
or
tu
m
or
th
ic
kn
es
s
w
as
us
ed
.
O
S
H
R
:N
A
C
-i
n
de
x:
0.
64
N
A
D
SS
H
R
:N
A
C
-i
n
de
x:
0.
63
N
A
H
o
et
al
,2
01
7
(U
SA
)
14
55
4
T
1-
4
N
0-
3
T
cl
as
si
fi
ca
ti
on
N
cl
as
si
fi
ca
ti
on
Su
rg
er
y,
N
ec
k
di
ss
ec
ti
on
%
N
A
T
h
e
A
JC
C
8
sh
ow
ed
go
od
pr
og
n
os
ti
c
va
lu
e
th
at
im
pr
ov
ed
by
in
co
rp
or
at
io
n
of
n
um
be
r
of
m
et
as
ta
ti
c
n
od
es
to
N
cl
as
si
fi
ca
ti
on
.
O
S
2.
96
(2
.2
3-
3.
92
)*
3.
68
(3
.2
5-
4.
16
)*
*
<
.0
01
*
<
.0
01
**
M
at
os
et
al
,2
01
7
(B
ra
zi
l)
29
8
pT
1-
3
pN
1-
3
pT
cl
as
si
fi
ca
ti
on
,
pN
cl
as
si
fi
ca
ti
on
Su
rg
ic
al
re
se
ct
io
n
an
d
n
ec
k
di
ss
ec
ti
on
(a
ll
ca
se
s)
22
.8
%
in
pT
,2
9.
2%
in
pN
A
JC
C
8
al
lo
w
s
a
be
tt
er
st
ra
ti
fi
ca
ti
on
of
O
SC
C
ca
se
s.
C
as
es
th
at
re
ce
iv
ed
up
st
ag
in
g
in
pT
an
d/
or
pN
cl
as
si
fi
ca
ti
on
h
av
e
a
w
or
se
O
S
an
d
D
F
S.
O
S
N
A
.0
17
*
<
.0
01
**
D
SS
N
A
.0
07
*
.0
01
**
D
F
S
.0
02
*
A
lm
an
gu
sh
et
al
,
20
18
(F
in
la
n
d
&
B
ra
zi
l)
31
1
T
1-
3
cT
cl
as
si
fi
ca
ti
on
Su
rg
er
y
16
.7
%
A
JC
C
8
pr
ov
id
es
be
tt
er
pr
og
n
os
ti
ca
ti
on
th
an
A
JC
C
7
an
d
ca
n
be
fu
rt
h
er
op
ti
m
iz
ed
.
D
SS
2.
21
(1
.0
5-
4.
64
)
2.
37
(1
.1
2-
4.
99
)
.0
36
.0
23
D
F
S
2.
08
(1
.0
7-
4.
01
)
2.
12
(1
.0
9-
4.
08
)
.0
3
.0
27
A
m
it
et
al
,2
01
8
(U
SA
)
24
4
I-
IV
O
ve
ra
ll
st
ag
e,
pT
cl
as
si
fi
ca
ti
on
,
pN
cl
as
si
fi
ca
ti
on
Su
rg
er
y
25
%
A
JC
C
8
al
lo
w
s
fo
r
be
tt
er
ri
sk
st
ra
ti
fi
ca
ti
on
of
O
T
SC
C
th
an
A
JC
C
7.
O
S
13
.7
2
(2
.3
9-
10
5.
3)
<
.0
5
D
SS
14
.4
1
(4
.1
8-
14
5.
2)
<
.0
5
C
ra
m
er
et
al
,2
01
8
(U
SA
)
39
36
1
I-
IV
T
cl
as
si
fi
ca
ti
on
,
N
cl
as
si
fi
ca
ti
on
Su
rg
er
y,
R
T
,C
T
,C
R
T
10
%
A
JC
C
8
up
st
ag
ed
a
su
bs
ta
n
ti
al
n
um
be
r
of
ca
se
s
an
d
th
at
sl
ig
h
tl
y
im
pr
ov
ed
th
e
pr
og
n
os
ti
ca
ti
on
in
O
SC
C
.
O
S
(T
cl
as
si
fi
ca
ti
on
)
5.
34
(4
.7
7–
5.
98
)
3.
86
(3
.4
4-
4.
33
)
N
A
O
S
(N
cl
as
si
fi
ca
ti
on
)
3.
31
(2
.9
0-
3.
78
)
2.
48
(2
.1
6-
2.
84
)
N
A
K
an
o
et
al
,2
01
8
(J
ap
an
)
11
2
T
1-
4
T
cl
as
si
fi
ca
ti
on
Su
rg
er
y,
C
R
T
(n
=
3)
,B
T
(n
=
2)
23
.2
%
T
3
of
A
JC
C
8
is
re
as
on
ab
le
in
pr
og
n
os
ti
ca
ti
on
;w
h
ile
T
2
re
pr
es
en
ts
a
h
et
er
og
en
ou
s
gr
ou
p
of
ca
se
s.
D
SS
N
A
<
.0
1
N
od
al
m
et
as
ta
si
s
N
A
<
.0
1
L
ia
o
et
al
,2
01
8
(T
ai
w
an
)
19
33
pN
0-
N
3b
pN
cl
as
si
fi
ca
ti
on
Su
rg
er
y
%
N
A
pN
cl
as
si
fi
ca
ti
on
of
A
JC
C
8
sh
ow
ed
go
od
ri
sk
st
ra
ti
fi
ca
ti
on
of
O
S,
D
D
S
an
d
D
F
S;
bu
t
le
ss
us
ef
ul
st
ra
ti
fi
ca
ti
on
fo
r
di
st
an
t
m
et
as
ta
si
s.
O
S
N
A
<
.0
01
D
SS
N
A
<
.0
01
D
F
S
N
A
<
.0
01
M
as
ci
tt
ie
t
al
,2
01
8
(I
ta
ly
)
73
I-
IV
O
ve
ra
ll
st
ag
e,
pT
cl
as
si
fi
ca
ti
on
,
pN
cl
as
si
fi
ca
ti
on
Su
rg
er
y;
N
ec
k
di
ss
ec
ti
on
(a
ll
ca
se
s)
23
.3
%
A
JC
C
8
al
lo
w
s
fo
r
be
tt
er
ri
sk
st
ra
ti
fi
ca
ti
on
fo
r
T
SC
C
ca
se
s.
O
S
N
A
<
.0
5
D
F
S
N
A
<
.0
5
M
oe
ck
el
m
an
n
et
al
,
20
18
(A
us
tr
al
ia
)a
66
3
I-
IV
O
ve
ra
ll
st
ag
e
Su
rg
er
y
35
.6
%
A
JC
C
8
pe
rf
or
m
s
be
tt
er
st
ra
ti
fi
ca
ti
on
fo
r
su
rv
iv
al
of
O
SC
C
.
O
S
6.
91
(3
.8
0-
12
.5
6)
.0
00
D
SS
10
.2
2
(4
.5
7-
22
.8
4)
.0
00
M
oe
ck
el
m
an
n
et
al
,
20
18
(A
us
tr
al
ia
)a
32
5
II
I-
IV
N
cl
as
si
fi
ca
ti
on
Su
rg
ic
al
re
se
ct
io
n
an
d
n
ec
k
di
ss
ec
ti
on
(a
ll
ca
se
s)
45
.8
%
R
is
k
st
ra
ti
fi
ca
ti
on
of
A
JC
C
8
is
be
tt
er
in
O
SC
C
th
an
in
cu
ta
n
eo
us
SC
C
.H
ow
ev
er
,
pe
rf
or
m
an
ce
w
as
re
la
ti
ve
ly
po
or
in
bo
th
ca
n
ce
rs
.
O
S
3.
6
(2
.0
7-
6.
22
)
.0
00
D
SS
4.
4
(2
.2
1-
8.
60
)
.0
00 (
C
on
ti
n
ue
s)
ALMANGUSH ET AL. 3
T
A
B
L
E
1
(C
on
ti
n
ue
d)
F
ir
st
A
u
th
or
et
al
,
ye
ar
(C
ou
n
tr
y)
N
o.
of
ca
se
s
St
ag
e
8t
h
A
JC
C
an
al
yz
ed
M
ai
n
tr
ea
tm
en
t
%
of
ca
se
s
u
p
st
ag
ed
M
ai
n
fi
n
d
in
gs
re
ga
rd
in
g
p
ro
gn
os
ti
c
p
er
fo
rm
an
ce
of
A
JC
C
8
O
u
tc
om
e
H
R
(9
5%
C
I)
P
va
lu
e
Po
lla
er
s
et
al
,2
01
8
(A
us
tr
al
ia
)
11
8
I-
IV
O
ve
ra
ll
st
ag
e,
T
cl
as
si
fi
ca
ti
on
Su
rg
er
y
27
.1
%
A
JC
C
8
pr
ov
id
es
im
pr
ov
ed
st
ra
ti
fi
ca
ti
on
fo
r
D
F
S
in
O
SC
C
.
O
S
.0
00
2
D
F
S
.0
00
2
D
F
S
(T
cl
as
si
fi
ca
ti
on
)
.0
19
Su
br
am
an
ia
m
et
al
,
20
18
(I
n
di
a)
b
44
1
T
1-
2
T
cl
as
si
fi
ca
ti
on
Su
rg
ic
al
re
se
ct
io
n
(w
it
h
or
w
it
h
ou
t
R
T
or
C
R
T
)
51
.7
%
A
JC
C
ac
h
ie
ve
d
a
be
tt
er
pr
og
n
os
ti
ca
ti
on
of
O
S
in
ea
rl
y
O
SC
C
.
O
S
(O
R
)
2.
34
(1
.5
3-
1.
58
)
2.
46
(1
.1
5-
5.
26
)
<
.0
01
.0
21
T
ir
el
li
et
al
,2
01
8
(I
ta
ly
)
17
4
pT
1-
4
N
0-
3
pT
cl
as
si
fi
ca
ti
on
pN
cl
as
si
fi
ca
ti
on
Su
rg
er
y
31
%
fo
r
pT
,1
4%
fo
r
pN
A
JC
C
8
im
pr
ov
ed
di
sc
ri
m
in
at
io
n
of
T
cl
as
si
fi
ca
ti
on
fo
r
an
al
ys
is
of
D
SS
D
SS
N
A
.0
1
(f
or
pN
,.
00
1)
V
ui
ty
et
al
,2
01
8
(U
K
)
44
9
pT
1-
4
pN
0-
3
pT
cl
as
si
fi
ca
ti
on
Su
rg
er
y
%
N
A
A
JC
C
8
pr
ov
id
ed
a
be
tt
er
di
st
ri
bu
ti
on
th
an
th
at
in
A
JC
C
7.
H
ow
ev
er
,A
JC
C
8
di
d
n
ot
di
sc
ri
m
in
at
e
be
tw
ee
n
pa
ti
en
ts
w
it
h
T
3
an
d
T
4.
O
S
N
A
<
.0
00
1
D
SS
N
A
<
.0
00
1
W
ei
m
ar
et
al
,2
01
8
(C
an
ad
a)
c
33
5
T
1-
4
T
cl
as
si
fi
ca
ti
on
Su
rg
er
y
%
N
A
A
JC
C
8T
cl
as
si
fi
ca
ti
on
ca
n
be
cl
as
si
fi
ed
us
in
g
ra
di
ol
og
ic
th
ic
kn
es
s/
de
pt
h
an
d
sh
ow
ed
in
cr
em
en
ta
lH
R
w
it
h
h
ig
h
er
T
cl
as
si
fi
ca
ti
on
.
O
S
4.
2
(1
.7
7-
9.
95
)
<
.0
01
Ja
in
et
al
,2
01
9
(I
n
di
a)
34
2
I-
IV
pT
cl
as
si
fi
ca
ti
on
pN
cl
as
si
fi
ca
ti
on
Su
rg
er
y
w
it
h
n
ec
k
di
ss
ec
ti
on
38
.8
%
fo
r
pT
;3
7.
3%
fo
r
pN
pN
w
as
th
e
m
os
t
po
w
er
fu
l
pr
og
n
os
ti
ca
to
r
fo
r
O
SC
C
.
O
S
4.
24
(2
.2
0-
8.
14
)
<
.0
01
D
F
S
7.
63
(4
.3
0-
13
.5
6)
<
.0
01
L
ee
et
al
,2
01
9
(R
ep
ub
lic
of
K
or
ea
)
34
5
I-
IV
O
ve
ra
ll
st
ag
e,
N
cl
as
si
fi
ca
ti
on
Su
rg
er
y
an
d
n
ec
k
di
ss
ec
ti
on
%
N
A
A
JC
C
8
ov
er
al
ls
ta
ge
(I
-I
V
)
sh
ow
ed
go
od
ri
sk
st
ra
ti
fi
ca
ti
on
.I
n
co
rp
or
at
io
n
of
n
um
be
r
of
po
si
ti
ve
L
N
w
it
h
N
cl
as
si
fi
ca
ti
on
im
pr
ov
ed
th
e
pr
og
n
os
ti
ca
ti
on
of
A
JC
C
8.
O
S
11
.1
3
(5
.4
1-
22
.8
9)
<
.0
01
D
SS
22
.8
7
(7
.9
9-
65
.4
9)
<
.0
01
D
F
S
11
.5
0
(5
.1
5-
25
.6
8)
<
.0
01
M
ur
th
y
et
al
,2
01
9
(I
n
di
a)
b
44
1
I-
II
T
cl
as
si
fi
ca
ti
on
W
id
e
ex
ci
si
on
an
d
n
ec
k
di
ss
ec
ti
on
51
.7
%
In
ea
rl
y
O
SC
C
,A
JC
C
8
pr
ov
id
es
be
tt
er
su
rv
iv
al
pr
ed
ic
ti
on
th
an
A
JC
C
7.
O
S
N
A
<
.0
17
D
SS
N
A
<
.0
16
D
F
S
N
A
<
.0
5
R
aj
ap
pa
a
et
al
,2
01
9
(I
n
di
a)
14
31
T
1-
4
N
0-
3
T
cl
as
si
fi
ca
ti
on
N
cl
as
si
fi
ca
ti
on
Su
rg
er
y
%
N
A
B
ot
h
T
cl
as
si
fi
ca
ti
on
an
d
N
cl
as
si
fi
ca
ti
on
sh
ow
ed
go
od
ri
sk
st
ra
ti
fi
ca
ti
on
,a
n
d
au
th
or
s
re
co
m
m
en
de
d
in
co
rp
or
at
io
n
of
n
um
be
r
of
po
si
ti
ve
L
N
in
th
e
st
ag
in
g
sy
st
em
.
O
S
3.
60
(2
.3
4-
5.
53
)*
<
.0
01
*
D
F
S
3.
25
(2
.4
7-
4.
28
)*
*
<
.0
01
**
N
ot
es
:S
ta
ti
st
ic
al
va
lu
es
fr
om
ea
ch
st
ud
y
w
er
e
fo
r
th
e
h
ig
h
es
t
ov
er
al
l
st
ag
e,
T
cl
as
si
fi
ca
ti
on
an
d/
or
N
cl
as
si
fi
ca
ti
on
.V
al
ue
s
in
bo
ld
ar
e
fr
om
m
ul
ti
va
ri
ab
le
an
al
ys
is
.*
va
lu
es
fo
r
T
-c
la
ss
if
ic
at
io
n
.
**
va
lu
es
fo
r
N
-c
la
ss
if
ic
at
io
n
.
A
bb
re
vi
at
io
n
s:
B
T
,b
ra
ch
yt
h
er
ap
y;
C
I,
co
n
fi
de
n
ce
in
te
rv
al
;
C
R
T
,c
h
em
or
ad
ia
ti
on
th
er
ap
y;
C
T
,c
h
em
ot
h
er
ap
y;
D
F
S,
di
se
as
e-
fr
ee
su
rv
iv
al
;
D
SS
,d
is
ea
se
-s
pe
ci
fi
c
su
rv
iv
al
;
H
R
,h
az
ar
d
ra
ti
o;
L
N
,
ly
m
ph
n
od
e;
N
A
,n
ot
av
ai
la
bl
e;
O
S,
ov
er
al
ls
ur
vi
va
l;
O
R
,O
dd
s
ra
ti
o;
R
T
,r
ad
ia
ti
on
th
er
ap
y.
a D
ir
ve
n
et
al
(2
01
7)
an
d
M
oe
ck
el
m
an
n
et
al
(2
01
8)
ar
e
ov
er
la
pp
ed
.
b
Su
br
am
an
ia
m
et
al
(2
01
8)
an
d
M
u
rt
h
y
et
al
(2
01
9)
ar
e
ov
er
la
pp
ed
.
c W
ei
m
ar
et
al
(2
01
8)
u
se
d
ra
di
ol
og
ic
m
ea
su
re
m
en
t
of
tu
m
or
de
pt
h
/t
h
ic
kn
es
s
to
re
-s
ta
ge
T
cl
as
si
fi
ca
ti
on
ac
co
rd
in
g
to
cr
it
er
ia
of
A
JC
C
8.
4 ALMANGUSH ET AL.
2.3 | Statistical analysis
The meta-analysis of hazard ratios (HR) was performed
by the “meta” package (version 4.8-1) in statistical soft-
ware R (version 3.4.0). For each analysis, we carried out
an inverse variance-weighted fixed-effects analysis and a
DerSimonian-Laird random effects analysis.10 We consid-
ered the random effects analysis as our main result to
account for heterogeneity between the studies. In addi-
tion to the meta-analyzed effect sizes, our results also
included the estimated proportion of variation in effect
sizes due to heterogeneity (I2)11 and the DerSimonian-
Laird estimate of the variance of the effect sizes (t2).10
The confidence intervals reported by “meta” package are
based on the estimated SE and therefore can show a
slight numerical difference from the confidence intervals
reported in the original studies.
The reference group in HR calculation was stage I for
the overall stages II-IV, T1 for the T-classifications T2-T4,
and N0 for the N-classifications N1-N3. We excluded
from the meta-analysis a single study12 that reported HR
for N-classification with respect to category N1. Because
many studies had analyzed the advanced stage as one cat-
egory (eg, IV) and other studies provided detailed ana-
lyses of the subcategories (ie, IVa, IVb, IVc), we
conducted separate meta-analyses for each subcategory
for which HR and 95%CI were reported in two or more
studies. In addition, we combined the subcategories into
a single category by using inverse-variance weighting
within each study as follows: stage IVa, IVb, and IVc
were combined as stage IV; T4a and T4b were combined
as T4; N2a, N2b, and N2c were combined as N2; while
N3a and N3b were combined as N3. For those studies of
the overall stage (I-IV) that reported only Kaplan-Meier
curves without an HR estimate, we estimated the HR
manually following the approach presented by Tierney
et al.13 In Table 2, these estimates are highlighted by
Italic font. In detail, we extracted numerical information
from the Kaplan-Meier curves by using GraphClick 3.0.3
software. When both the curve coordinates and the cen-
soring information were visible in the original figure, we
used the Cox proportional hazards model as
implemented in “coxph” function of the R package “sur-
vival” (version 2.43-3) to estimate the HR and its SE.
When no censoring information was available, we
assumed that censoring was non-informative and that
patients were censored at a constant rate within any
given time interval.13 As the study by Cramer et al14 ana-
lyzed stages I-IV including a large number of samples
compared to other studies, we conducted an additional
meta-analysis for stages I-IV excluding this large cohort.
We used funnel plot to visually assess possible publica-
tion bias.
3 | RESULTS
3.1 | Search results
A total of 337 articles were retrieved, and there were 53
duplicates. A total of 284 hits were screened and 261 of
these were excluded as being irrelevant. Of the 23 studies
that were relevant, three studies15-17 were excluded
because they included different subsites of head and neck
cancer. Therefore, 20 studies were eligible as they evalu-
ated the prognostic performance of AJCC 8 in OSCC
(Figure 1). Of these, seven studies were from Asia,18-24
four were from Australia,12,25-27 four from Europe,28-31
four from North America,14,32-34 and one from South
America.35 In addition, a Brazilian cohort was analyzed
in one of the published studies combined with a Finnish
cohort.28 Most studies included different subsites of
OSCC, and only four studies included oral tongue SCC
without any other subsite.18,28,29,33 Overlapping studies
were from Australia12,25,26 and India20,21; and they were
not included together in the present meta-analysis.
3.2 | Meta-analysis results
There were seven studies (40 808 patients) eligible for
pooled analysis of overall stage (I-IV). This analysis (Fig-
ure 2A-C) showed that risk of mortality continued to
increase with each higher stage. Stage I was the reference
point for our pooled analysis (as in the original studies),
and a HR of 1.87 with 95% confidence interval (95%CI) of
1.78 to 1.96 was reported for stage II, HR 2.65 (95%CI 2.51-
2.80) for stage III, and HR 4.94 (95%CI 3.61-6.76) for stage
IV. The study with an exceptionally large number of
cases14 was then excluded from the meta-analysis of over-
all stage (I-IV) and the remaining six studies (1447
patients) were included in the second analysis (Figure 3A-
C). Consistently with the previous analysis, an increased
risk of mortality with each higher stage was observed with
HR 1.77 (95%CI 1.15-2.73) for stage II, 2.86 (95%CI 1.85-
4.42) for stage III, and 5.75 (4.27-7.75) for stage IV.
Out of the three subclasses of stage IV, we were able
to carry out meta-analyses (Figure 4 A, B) for stage IVa
with a HR of 3.46 (95%CI 3.31-3.61), and for stage IVb
with a HR of 7.09 (95%CI 4.85-10.36). We were not able
to conduct a meta-analysis for stage IVc because only one
study14 reported it.
In the meta-analysis for T classification (Figure S1A-
C), HR 1.98 (95%CI 1.51-2.59) was observed for T2, HR
3.12 (95%CI 2.19-4.45) for T3, and HR 3.71 (95%CI 3.28-
4.20) for T4, as compared to the reference category T1.
We were not able to conduct meta-analyses for T4a and
T4b subclasses separately because almost all published
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TABLE 2 Studies (with their statistical values) that were included in the meta-analyses
Overall stage (I-IV)
Study Total No. Stage HR (95%CI) Subclass: HR (CI)
Amit et al, 2018 244 Stage I
Stage II
Stage III
Stage IV
1.00
2.64 (0.43-17.98)
5.86 (1.51-52.69)
13.72 (2.39–105.3)
NA
Cramer et al, 2018 39 361 Stage I
Stage II
Stage III
Stage IV
1.00
1.87 (1.78-1.97)
2.65 (2.51-2.80)
3.79 (3.63-3.95) IVa 3.45 (3.31-3.61)
IVb 5.28 (4.88-5.71)
IVc 9.14 (8.39-9.94)
Mascitti et al, 2018 73 Stage I
Stage II
Stage III
Stage IV
1.00
1.90 (0.21-16.81)
2.87 (0.35-23.24)
9.28 (1.25-68.97)
NA
Moeckelmann et al, 2018 663 Stage I
Stage II
Stage III
Stage IV
1.00
1.67 (0.88-3.16)
1.57 (0.81-3.04)
4.51 (2.94-6.93) IVa 2.86 (1.54-5.31)
IVb 6.91 (3.80-12.56)
Pollaers et al, 2018 118 Stage I
Stage II
Stage III
Stage IV
1.00
2.52 (0.68-9.40)
3.23 (1.01-10.32)
4.43 (1.50-13.03) IVa 3.45 (1.13-10.59)
IVa 12.75 (3.46-46.98)
Jain et al, 2019 342 Stage I
Stage II
Stage III
Stage IV
1.00
0.72 (0.14-3.68)
3.97 (0.91-17.26)
5.33 (1.29-21.95) IVa 4.30 (1.03-18.041)
IVb 10.79 (2.45-47.63)
Lee et al, 2019 345 Stage I
Stage II
Stage III
Stage IV
1.00
1.97 (0.87-4.50)
4.37 (2.12-8.99)
7.84 (4.74-12.99) IVa 5.61 (2.77-11.37)
IVa 11.13 (5.41-22.89)
T classification (T1-T4)
Ho et al, 2017 14 554 T1
T2
T3
T4
1.00
1.54 (1.12-2.11)
2.12 (1.59-2.81)
2.96 (2.23-3.92)
NA
Cramer et al, 2018 39 361 T1
T2
T3
T4
1.00
2.00 (1.91-2.09)
3.32 (3.14-3.51)
3.84 (3.68-4.00) T4a 3.64 (3.48-3.81)
T4b 5.34 (4.77-5.98)
Weimar et al, 2018 335 T1
T2
T3
T4
1.00
1.67 (0.72-3.88)
2.88 (1.26-6.58)
4.2 (1.77-9.95)
NA
Rajappaa et al, 2019 1431 T1
T2
T3
T4
1.00
4.06 (2.03-8.10)
6.23 (3.11-12.5)
4.71 (2.24-9.89)
NA
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studies reported HR and 95%CI for T4 classification as
one category. Cramer et al14 was the only study that pro-
vided detailed analysis for T4a and T4b as explained in
Table 2.
For N classification (Figure S2A-C), an increased risk
with each higher N classification was observed with HR
1.79 (95%CI 1.50-2.13) for N1, 2.67 (95%CI 2.59-2.77) for
N2 and 3.68 (95%CI 3.41-3.97) for N3, as compared to the
reference of N0. Only two studies14,32 were eligible for
the meta-analyses of the subclasses of N2 and N3 classifi-
cations. The meta-analyses showed a HR of 1.91 (95%CI
1.83-2.00) for N2a, 2.26 (95%CI 2.02-2.52) for N2b, 2.55
(95%CI 2.45-2.67) for N2c, 3.09 (95%CI 2.91-3.28) for N3a,
and a HR of 4.13 (95%CI 3.59-4.76) for N3b
subclassification.
Out of all meta-analyses, the heterogeneity measure
I2 showed high heterogeneity (I2 > 75%)11 only for T3
classification (Figure S1B) where I2 was 76%.
3.3 | Publication bias
Funnel plots were created for each pooled analysis of
stages II-IV (Figures S3 and S4) as well as for stage IVa
and IVb (Figure S5). In Figure S3C, the funnel plot
showed asymmetry with the smaller studies showing
higher effects compared to the meta-analysis result.
When the largest study by Cramer et al14 was excluded
(Figure S4C), the asymmetry disappeared. Hence, it
seems likely that the asymmetry in Figure S3C was due
to a relatively small effect size estimate in the single large
study of Cramer et al14 rather than due to a publication
bias among the smaller studies. Other funnel plots than
that in Figure S3C did not show asymmetry.
4 | DISCUSSION
Staging of OSCC is the cornerstone to proper treatment
planning to avoid overtreatment or undertreatment. The
AJCC staging system (ie, TNM) has been used for
decades as a universal system for risk stratification. How-
ever, AJCC has been criticized during the last decade due
to suboptimal performance in prognostication of
OSCC.36-38 Recently, the AJCC has released the eighth
edition with major changes in staging of some cancers
(including OSCC) to improve risk stratification.5 Our cur-
rent study meta-analyzed the relevant studies of OSCC
and found a good risk stratification based on the new
criteria of AJCC 8. However, further adjustment of AJCC
8 is discussed based on the published studies.
The new criteria of AJCC 8 incorporate depth of inva-
sion into the T classification. The approach of including
depth of cancer infiltration into the TNM staging system
TABLE 2 (Continued)
Overall stage (I-IV)
Study Total No. Stage HR (95%CI) Subclass: HR (CI)
N classification (N0-N3)
Ho et al, 2017 14 554 N0
N1
N2
N3
1.00
1.59 (1.37-1.84)
2.62 (2.36-2.91)
3.65 (3.23-4.13)
N2a 2.27 (1.84-2.81)
N2b 2.70 (2.35-3.10)
N2c 2.91 (2.25-3.75)
N3a 2.04 (0.65-6.36)
N3b 3.68 (3.25-4.16)
Cramer et al, 2018 39 361 N0
N1
N2
N3
1.00
1.95 (1.86-2.05)
2.68 (2.59-2.78)
3.69 (3.35-4.06)
N2a 2.25 (1.98-2.57)
N2b 2.54 (2.43-2.66)
N2c 3.1 (2.91-3.3)
N3a 4.18 (3.63-4.83)
N3b 3.31 (2.9-3.78)
Jain et al, 2019 342 N0
N1
N2
N3
1.00
1.82 (0.83-4.04)
2.48 (1.34-4.60)
4.24 (2.20-8.14)
NA
Notes: Hazard ratio (HR) and 95% confidence interval (CI) that in Italic font were calculated from Kaplan-Meier curves. Underlined values
refer to combination of the subclassifications into a single class to make them comparable to other studies.
Abbreviation: NA: not available.
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is routinely used in some malignancies such as mela-
noma and colorectal cancer.38 In OSCC, the incorpora-
tion of depth of invasion (DOI) into T-classification was
proposed by Ebrahimi et al39 in 2014 based on a large
cohort from 11 cancer centers worldwide. In addition,
the significance of DOI has also been underlined in other
studies.40-43 The AJCC 8 has defined DOI as measure-
ment from the basement membrane of the adjacent nor-
mal mucosa to the deepest point of tumor invasion.
AJCC emphasized that depth of invasion and not tumor
thickness should be incorporated into the T classification.
Of note, Dirven et al25 in their recent analysis of a large
cohort of OSCC found almost the same performance for
the T classification (AJCC 8) while using depth or thick-
ness. Moreover, another recent study34 reported that the
T classification of AJCC 8 can be classified using radio-
logic (preoperative CT or MR imaging) measurements of
tumor thickness. This is an important finding for preop-
erative staging based on AJCC 8 and requires further
validation.
In another proposal, Subramaniam et al21 proposed
incorporating adverse histopathologic features such as
perineural invasion into the T classification.
Furthermore, Ebrahimi et al44 showed that patients with
medullary bone invasion have widely disparate prognoses
based on the size of the primary tumor and not all of
these patients should be classified as T4. For instance,
tumors with bone invasion limited to the cortex would
have a similar prognosis to those without bone invasion.
They thus proposed upstaging by one T classification in
case of medullary bone invasion.44 Validation of the inde-
pendent predictive impact of cortical vs medullary inva-
sion will be needed before de-staging of a subgroup of T4
tumors can be performed and treatment protocols de-
escalated.
It is noteworthy that only a very small risk difference
between T3 (HR 3.32, 95%CI 3.14-3.51) and T4a (HR
3.64, 95%CI 3.48-3.81) was observed by Cramer et al14
who included a large cohort in their analysis. However,
the reported HR for T4b (5.34, 95% 4.77-5.98) showed a
considerable difference from T3 or T4a classifications. In
our meta-analysis, we noted a very close risk between T3
classification (HR 3.12, 95%CI 2.19-4.45) and T4 classifi-
cation (HR 3.71, 95%CI 3.28-4.20). This was also noted in
two of the included studies with the largest cohorts.14,32
However, because other studies (Table 2) did not analyze
FIGURE 1 PRISMA Flowchart of our literature search and selection of studies
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T classification in large cohorts, we should interpret the
result of our meta-analysis regarding advanced T classifi-
cation (ie, T3 and T4) with caution. This issue requires
future research based on large cohorts to reach a defini-
tive conclusion about risk differences between T3 and T4.
Of note, Liao et al45 recommended to maintain extrin-
sic muscle invasion for classification of pT4 tumors as the
outcome of such tumors was poorer than that of pT3
tumors. On the other hand, Barrett et al46 supported the
removal of invasion of extrinsic muscles of the tongue
FIGURE 2 Forest plots of the pooled analysis of all eligible
studies for stage II (panel A), stage III (panel B) and stage IV
(panel C)
FIGURE 3 Forest plots of the pooled analysis of 6 eligible
studies for stage II (panel A), stage III (panel B) and stage IV (panel
C) after excluding Cramer et al that included an extremely large
number of cases compared to these 6 studies
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from pT4a. Also another recent study47 has accepted the
removal of the involvement of extrinsic muscles from T4
because the lingual extrinsic muscles are not deep and
sometimes superficial cancers involve them. It seems that
this issue about exclusion of extrinsic muscle involve-
ment requires further studies as the published papers on
AJCC 8 did not widely focus on it.
For nodal staging, AJCC 8 incorporated extranodal
extension into the N classification to improve the prog-
nostic performance of the TNM system. In patients with
OSCC, as well as in those with other cancers of head and
neck, extranodal extension is a common microscopic fea-
ture and it was widely reported as a promising prognostic
factor to identify cases at high-risk of worse progno-
sis.16,48 The impact of including extranodal extension into
the N classification of AJCC 8 has been analyzed in many
studies (Table 1). Our meta-analysis showed an incre-
mental increase in risk of worse survival with each
higher N classification of AJCC 8 (Figure S2). It is specu-
lated that a case of OSCC with numerous ipsilateral posi-
tive lymph nodes will have a worse survival compared
with a case with only one or two positive nodes.32 Inter-
estingly, Ebrahimi et al49 based on an international mul-
ticenter cohort have reported on promising significance
of the number of metastatic lymph nodes in OSCC.
Therefore, some of the studies that assessed the perfor-
mance of AJCC 8 showed that the number of positive
metastatic nodes can be a good modifier for the N classifi-
cation.23,24,32 Findings of these studies should be consid-
ered for future research as they might be useful for
further improvement of TNM staging.
Of note, upstaging of several cases was a common
phenomenon in the published studies (Table 1) when the
patient cohorts were re-staged according to AJCC 8. For
example, re-staging of our multicenter cohort according
to AJCC 850 showed upstaging of many “early-stage”
cases (ie, T1 or T2) to T3 which would be considered as
an “advanced-stage”. Dirven et al25 reported that 20.7%
of T1 tumors (based on AJCC 7) were upstaged to T2 and
6.7% upstaged to T3 when AJCC 8 was applied; in addi-
tion, 39.9% of T2 (based on AJCC 7) were upstaged to T3.
In another study, Matos et al35 reported on upstaging of
22.8% of cases based on pT classification, and upstaging
of 29.2% based on the pN classification criteria of AJCC
8. In the study by Amit et al,33 25% of all cases were
upstaged, and 12% of them were considered as early stage
(I-II) according to AJCC 7 but advanced stage (III-IV)
according to AJCC 8. In Mascitti et al29 study, 20.5% were
upstaged when DOI was included in the pT classification,
and 13.7% were upstaged when ENE was included in the
pN classification. In general, the proportion of upstaged
cases (when re-classified according to AJCC 8) ranged in
the published cohorts from 10%14 to 51.7%20 depending
on how many deep tumors and/or ENE-positive cases
were included in these cohorts (Table 1). Moreover, a
“two-step” upstaging (eg, from stage I to stage III) was
noted in the published studies.21,28
The above-mentioned upstaging will indeed influence
treatment planning. For example, an early stage T1
tumor without nodal involvement is usually treated by
surgical excision only, while a T3 tumor is considered as
a locally advanced case requiring both surgical resection
and adjuvant therapy. In the current era of upstaging
caused by AJCC 8, a case with a small T1 or T2 tumor
based on AJCC 7 will be upstaged to T3 if the depth of
invasion is more than 10 mm. The role of adjuvant ther-
apy in such cases is still not clear.51 However, Ebrahimi
et al52 have recently emphasized that depth alone (ie, in
absence of other risk factors such as nodal metastasis or
close margin) should not be used as an indication of post-
operative radiotherapy in patients with a small OSCC.
This is supported by the finding from another recent
study53 concluding that in case of a small oral tongue
cancer (≤2 cm) with DOI > 4 mm, the presence of at
FIGURE 4 Forest plots of the pooled analysis of all eligible
studies that reported stage IVa (panel A) and stage IVb (panel B)
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least two adverse features (eg, perineural invasion and
lymphovascular invasion) will warrant the consideration
of adjuvant therapy. Indeed, multimodality treatment
based on multiple adverse prognostic indicators is practi-
cally safer than a treatment decision based on a single
parameter. In general, any proposed change in the treat-
ment protocol based on AJCC 8 should be considered
with caution because the current evidence is based on
data of retrospective nature. Future research should ide-
ally consider prospective trials to analyze the treatment
implications caused by AJCC 8.
The endpoints of survival analyses (overall survival,
disease-specific survival or disease-free survival) and the
examined classification/stage (T classification, N classifi-
cation, or overall stage) were not similar between some
of the published studies (Table 1). We considered overall
survival when we conducted our meta-analyses because
this endpoint was the most commonly reported in the
published studies. Of note, the findings of our meta-anal-
ysis were consistent with almost all of the publications
indicating a good prognostic performance of AJCC 8 (I-
IV). We also noted that studies examining the signifi-
cance of AJCC 8 in cohorts of mucosal squamous cell car-
cinoma from different subsites of the head and neck,
including the oral cavity, have shown a good prognostic
performance of AJCC 8.15-17 Even though some authors
have criticized the complexity of AJCC 8 due to the inclu-
sion of depth of invasion and extranodal extension, they
have, however, also reported a useful performance of
AJCC 8.26 The published studies have cohorts from differ-
ent geographic regions (Asia, Australia, Europe, North
America, and South America) with different ethnic
groups and with variable socioeconomic status. This
might indicate that AJCC 8 can be used worldwide for
staging of OSCC.
Many studies compared the prognostic ability of both
staging systems (ie, AJCC 7 and AJCC 8) using concor-
dance index (C-index). For example, Cramer et al14
reported an improvement in the survival concordance
index from 0.714 (AJCC 7) to 0.715 (AJCC 8) for clinical
staging, and an improvement from 0.699 (AJCC 7) to
0.704 (AJCC 8) for pathologic staging. In the study by
Moeckelmann et al,26 AJCC 8 showed a better prognostic
performance (0.70) than AJCC 7 (0.65) for overall sur-
vival, and for disease-specific survival (0.74 vs 0.69). Simi-
lar superior prognostic performance for AJCC 8 in
analysis of overall and disease-specific survival was
reported by Amit et al33; and a modest predictive perfor-
mance (C-index 0.66) was found in two other studies.12,22
In addition, the promising performance of AJCC 8 has
also been reported using Akaike information criterion
(AIC) in some studies of OSCC.26,33 Moreover, many
other studies that did not report the C-index or AIC have
reported that AJCC 8 allows for better risk stratification
(than AJCC 7) for OSCC cases as indicated by the prog-
nostic values and survival curves.20,21,27-30 Interestingly,
AJCC 8 has demonstrated a good prognostic performance
in recent studies on gastric cancer,54,55 breast cancer56,57
and lung cancer.58 In cutaneous squamous cell carci-
noma of the head and neck, a weaker prognostic perfor-
mance (C-index 0.58 for overall survival and 0.61 for
disease-specific survival) has been reported.12
The distribution of patients between risk categories of
T classification, N classification, and overall TNM stage
(I-IV) for all studies analyzed AJCC 8 is summarized in
Table 3. We noted that there were small percentages of
cases in some advanced subclasses (IVb, IVc, T4b, N2a,
N2b, N2c, or N3a). Specifically for N3a, there were no
cases or a very small population in the relevant stud-
ies19,32,33,35 that reported the subclasses of N classification
(Table 3). A possible explanation for the lack of N3a cases
is that it is rare for a nodal metastasis of more than 6 cm
in diameter not to have ENE, and therefore, cases with
such advanced nodal classification were all categorized as
N3b in the published studies.19,26,32,33,35 Future studies
should analyze this issue of advanced nodal staging in
larger cohorts to find out whether missing ENE (due to
for example sampling error) cannot influence the classifi-
cation in cases of nodal metastasis of more than 6 cm in
diameter.
In addition to lack of clear evidence for the difference
between the reported T classification (T3 vs T4), also
other limitations should be acknowledged. Firstly, major-
ity of the published studies included patients with differ-
ent oral cavity subsites. It is important to examine the
AJCC 8 in separate cohorts of oral subsites as the clinical
behavior and survival outcome do vary between the sub-
sites. Secondly, majority of studies that reported the haz-
ard ratio for T classification have considered T4 as one
group without identifying the difference between T4a
(which is curable) and T4b (which is often incurable).
Only the study by Cramer et al14 reported the hazard
ratio for T4a separately from T4b with a little higher risk
of the latter one in multivariate analysis. Due to this
shortcoming in majority of the published studies, we
were not able to show the difference in risk between T4a
and T4b in our meta-analysis. The third limitation is that
the analyses of the advanced subclasses of N classification
(ie, N2a, N2b, N2c; N3a, N3b) have been reported in only
a few studies,14,32 and therefore our meta-analyses of
these subclasses should be interpreted with caution.
Fourthly, the inappropriate grouping of some cases (that
may be due to overlapping between some risk categories)
should be acknowledged. Finally, individual cohorts were
relatively small (except for Cramer et al14). These short-
comings should be avoided in future studies.
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TABLE 3 The distribution of cases between risk categories of T classification, N classification and overall TNM stage (I-IV) for studies
applying AJCC 8
First Author et al, year (Country) No. of cases T classification N classification Overall TNM
Dirven et al, 2017 (Australia) 456 pT1 18.6%
pT2 30.3%
pT3 34.0%
pT4 17.1%
NA NA
Ho et al, 2017 (USA) 14 554 NA N0 64.1%
N1 9.4%
N2a 3.2%
N2b 8.1%
N2c 1.9%
N3a 0.1%
N3b 13.3%
NA
Matos et al, 2017 (Brazil) 298 pT1 11.7%
pT2 14.4%
pT3 29.9%
pT4 44.4%
pN0 45.4%
pN1 8.9%
pN2a 6.5%
pN2b 10.1%
pN2c 4.8%
pN3a 0.0%
pN3b 24.3%
NA
Almangush et al, 2018 (Finland & Brazil) 311 cT1 28.9%
cT2 64.6%
cT3 6.4%
All cases included were cN0 NA
Amit et al, 2018 (USA) 244 pT1 32.4%
pT2 49.6%
pT3 18.0%
pN0 70.1%
pN1 11.9%
pN2a 3.3%
pN2b 6.1%
pN2c 0.4%
pN3b 8.2%
NA
Cramer et al, 2018 (USA) 39 361 NA NA 0 4.8%
I 35.5%
II 19.1%
III 10.8%
IV 29.8%
IVa 25.1%
IVb 2.7%
IVc 2.0%
Kano et al, 2018 (Japan) 112 T1 17.86%
T2 37.5%
T3 42.86%
T4a 0.89%
T4b 0.89%
NA NA
Liao et al, 2018 (Taiwan) 1933 NA pN0 61.7%
pN1 9.3%
pN2 10.2%
pN3a 0.0%
pN3b 18.9%
NA
Mascitti et al, 2018 (Italy) 73 pT1 17.81%
pT2 38.36%
pT3 21.92%
pT4a 21.92%
pN0 46.58%
pN1 23.29%
pN2 17.81%
pN3 12.33%
I 6.85%
II 23.29%
III 23.29%
IVa 34.25%
IVb 12.33%
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With all these limitations in mind, however, the over-
all stage (I-IV) as recently described in the AJCC 8 stag-
ing manual provides a good risk stratification for OSCC.
Upstaging of cases was a common observation in the
published studies, and this reflects changes in treatment
planning. Further research should implement prospective
studies and multi-institutional collaboration when evalu-
ating AJCC 8 and examining its proposed modifications
TABLE 3 (Continued)
First Author et al, year (Country) No. of cases T classification N classification Overall TNM
Moeckelmann et al, 2018 (Australia) 663 NA NA I 18.8%
II 22.5%
III 20.9%
IVa 21.6%
IVb 16.2%
Moeckelmann et al, 2018 (Australia) 325 NA N0 was not included
N1 23.4%
N2a 8.6%
N2b 22.5%
N2c 5.2%
N3a 0.0%
N3b 40.3%
I, II were not included
III 16.6%
IV 83.4
Pollaers et al, 2018 (Australia) 118 NA NA I 25.4%
II 15.3%
III 24.6%
IVa 28.0%
IVb 6.8%
Subramaniam et al, 2018 (India) 441 T1 26.4%
T2 41.7%
T3 31.9%
NA NA
Tirelli et al, 2018 (Italy) 174 pT1 27.54%
pT2 24.55%
pT3 32.93%
pT4 14.97%
pN0 63.47%
pN1 10.18%
pN2 13.77%
pN3 12.57%
NA
Vuity et al, 2018 (UK) 449 pT1 32%
pT2 30%
pT3 22%
pT4 16%
NA NA
Weimar et al, 2018 (Canada) 335 — — —
Jain et al, 2019 (India) 342 pT1 10.6%
pT2 35.1%
pT3 28.9%
pT4 25.4%
pN0 55.0%
pN1 11.4%
pN2 20.2%
pN3 13.4%
I 9.1%
II 22.8%
III 20.5%
IV 47.6%
Lee et al, 2019 (Republic of Korea) 345 NA NA NA
Murthy et al, 2019 (India) 441 pT1 28.28%
pT2 40.27%
pT3 31.45%
NA NA
Rajappa et al, 2019 (India) 1431 NA N0 67.4%
N1 11.1%
N2 11.0%
N3 10.5%
NA
Summary of all studies in a weighted mannera pT1 20.12%
pT2 28.27%
pT3 28.74%
pT4 22.94%
pN0 59.78%
pN1 10.09%
pN2 12.76%
pN3 17.44%
I 15.95%
II 21.92%
III 21.30%
IV 40.84%
Note: Almangush et al (2018), Subramaniam et al (2018), and Murthy et al (2019) were designed for early-stage of OSCC.
aSummary was computed for all possible studies to provide % distribution of pT classification, pN classification, and TNM stage.
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for T and N classifications. Meanwhile, it can be rec-
ommended to use AJCC 8 in daily practice as it provides
successful risk stratification of OSCC cases.
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